Fisher & Paykel Healthcare Confirms No Material Impact on Earnings Guidance

Fisher & Paykel Healthcare announced today that settlement of the global patent infringement litigation with ResMed will not have a material impact on its net profit after tax guidance for the 2019 financial year.
The company provided earnings guidance in an announcement to the market on 26 November 2018 and the company expects no material impact to that guidance given the proximity of the settlement to the end of the company’s financial year and the legal fees expected to be incurred to withdraw the pending infringement cases.
More detail regarding the settlement of the global patent infringement litigation is available in the company’s corresponding press release.


About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea.  The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website






Marcus Driller
VP Corporate
+64 (0) 27 578 9663